
GLP-1 receptor agonists pose a lower risk of thyroid cancer compared to insulin in people with type 2 diabetes.


coremsg

Among people with type 2 diabetes who received a GLP-1 receptor agonist, there was less correlation between this treatment and thyroid cancer than among people with type 2 diabetes treated with insulin.

GLP-1s Like Semaglutide: Less Thyroid Cancer Than Insulin

glp-1-receptor-agonists-and-thyroid-cancer-risk-in-type-2-diabetes


GLP-1 Receptor Agonists and Thyroid Cancer Risk in Type 2 Diabetes
